Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Beyond Meat, Nikola, Newlox: meat replacement, hydrogen, and green gold

The quest for a better world coupled with economic success motivates investors around the globe to participate in innovation and business ideas. These are often subjects that promote health and protect the environment. Those who think big and plan ahead receive the relevant at...

Burcon, Canopy, dynaCERT - how cannabis, proteins and hydrogen improve the world

Innovations continuously change our lives. Entrepreneurs around the globe are trying to make things happen, developing products and technologies that are designed to improve everyday life. Business areas that are scalable are particularly successful. Once a product is ready to...

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed

The highlights of this investment story are outlined in a Zacks Small-Cap Research report. In a Nov. 19 research note, analyst David Bautz reported that Zacks Small-Cap Research initiated coverage on Avivagen Inc. (VIV:TSX.V; CHEXF:OTCMKTS) with a US$2.50 valuation....

Triple Threat Canbud Launches New Products Targeting the Hottest Health & Wellness Trends

After its public listing last October, shares in Canbud Distribution Corporation (CSE: CBDX | FSE: CD0) appear poised to move higher as it executes on its three-pronged business model. Canbud is a science and technology company that concentrates its attention on the Hea...

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...

China Social Media Firm Gains 55 Million Monthly Active Users

Weibo Corp. (WB:NASDAQ) , a leading Chinese social media platform company with nearly 500 million monthly active users, today announced its unaudited financial results for the second quarter ended June 30, 2019. In the report, the firm reported total n...

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. A small-cap Canadian company, Avivagen Inc. (VIV:TSX.V) , has developed a feed supplement, OxC-beta™ Livestock, wh...

Surface Oncology Shares Trade Up 40% on Phase1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. Clinical-...
1 2 3 4 5 6 7 8 9 10 ...